Table 4 Multivariate analysis of risk factor s for developing SSI
From: Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery
Factor | Effect size (95% CI) | P value |
|---|---|---|
Age | 1.09 (0.982–1.200) | 0.107 |
Male gender | 2.04 (0.418–9.990) | 0.378 |
Diabetes mellitus | 3.67 (0.908–14.900) | 0.068 |
Anticoagulant | 1.44 (0.310–6.690) | 0.642 |
ASA (1.2 or 3) | 1.87 (0.413–8.440) | 0.417 |
Site (stomach or colon) | 0.217 (0.0200–2.360) | 0.209 |
Approach (open or laparoscopy) | 0.636 (0.138–2.930) | 0.562 |
Use of olanexidine | 0.160 (0.0365–0.700) | 0.0150 |
Complication except SSI | 2.60 (0.657–10.300) | 0.173 |